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Human pluripotent stem cells (hPSCs) possess unlimited proliferative potential while
maintaining the ability to differentiate into any cell type including skeletal muscle cells
(SMCs). hPSCs are amenable to genetic editing and can be derived from patient somatic
cells, and thus represent a promising option for cell therapies for the treatment of
degenerative diseases such as muscular dystrophies. There are unresolved challenges
however associated with the derivation and scale-up of hPSCs and generation of
differentiated cells in large quantity and high purity. Reported myogenic differentiation
protocols are long, require cell sorting and/or rely on ectopic expression of myogenic
master regulators. More recent advances have been made with the application of small
molecules to enhance the myogenic differentiation efficiency and the identification of
more selective markers for the enrichment of myogenic progenitors with enhanced
regenerative potential. Here we review the field of myogenic differentiation and highlight
areas requiring further research.
Keywords: skeletal muscle cells, satellite cells, skeletal muscle, pluripotent, IPSC, pax7, MyoD, myogenic
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Introduction
Skeletal muscle has a great capacity to regenerate following muscle wasting caused by trauma or
disease. This regenerative potential is attributed primarily to skeletal-muscle resident stem cells
called satellite cells (SCs) that are distinguished by their expression of PAX7 and their location
between the basal lamina and the sarcolemma of myofibers (Wang and Rudnicki, 2012). In
Duchenne muscular dystrophy (DMD), a progressive muscle wasting caused by an absence of
functional Dystrophin protein, SCs are exhausted following many rounds of muscle degeneration
and regeneration (Heslop et al., 2000). Hence, SCs and their progeny (myoblasts) have been
considered as a promising candidate for cell replacement therapy for DMD and other types of
muscle disease (Skuk et al., 2014). There are several major limitations to the use of SCs as a
cell therapy including their paucity, difficulty to isolate, limited proliferative capacity and loss of
in vivo regenerative potential upon ex vivo expansion (Montarras et al., 2005). In addition, genetic
engineering of SCs is challenging without immortalization (Ousterout et al., 2013) or sustained
association with muscle fibers in ex vivo culture (Marg et al., 2014).
hPSCs such as human embryonic stem cells (hESCs) and induced pluripotent stem cells
(hiPSCs) possess two unique features that distinguish hPSCs from adult stem cells: unlimited
proliferative potential and ability to differentiate into any cell type including SMCs. With
the added benefits of being amenable to genetic editing (Li et al., 2015), hPSCs hold great
promise as a source of cell replacement therapy for degenerative diseases like DMD. hiPSCs
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are generated by the over-expression of a combination of master
pluripotency regulators (e.g., OCT4 (POU5F1), SOX2, KLF4,
MYC, LIN28, and NANOG), and can be generated from a
variety of somatic cell types from healthy donors and patients
(Takahashi et al., 2007; Yu et al., 2007; Abujarour et al., 2014).
hiPSCs thus evade the ethical and technical hurdles that limit
the clinical use of hESCs. Recent advances have been made in
the generation, defined culture and scale up of hiPSCs which are
prerequisite steps needed for any translation into the clinic. For
example, several non-integrating methods have been developed
to generate more clinically-compatible transgene-free hiPSCs,
albeit at reduced efficiencies (Wu et al., 2013). To enhance
reprogramming efficiency, a combination of small molecules
and more stringent cell sorting strategies were shown to enable
transgene-free single cell generation and maintenance of hiPSCs
under feeder cell-free conditions (Valamehr et al., 2012, 2014;
Abujarour et al., 2013). However, major challenges associated
with the clinical use of hPSCs remain, including the ability to
efficiently generate functional and engraftable differentiated cells,
including SMCs, in large quantity and high purity. Here we will
review the progress toward the differentiation of hPSCs into
SMCs.
Generation and Selection of Myogenic
Cells from hPSCs
In an early attempt to generate SMCs, hESCs were co-cultured
with stromal cells (OP9) to induce their differentiation into
multipotent mesenchymal precursors (Barberi et al., 2005). The
hESCs-derived mesenchymal precursors were enriched based on
their expression of CD73 and differentiated further into SMCs
that formed multinucleated myotubes when co-cultured with
mouse myoblastic line C2C12. Co-culture with stromal cells was
shown later by the same group to be unnecessary for generation
of SMCs from hESCs as prolonged culture of hESCs in fetal
bovine serum (FBS) and more elaborate enrichment stragety
could compensate for lower differentiation efficiency (Barberi
et al., 2007). With selection of mesenchymal precursors by
virtue of CD73 expression followed by expansion and another
round of cell sorting using the more skeletal muscle-specific
marker CD56 (NCAM), it was possible to obtain a culture
enriched withMYOD+ cells. Without the need to co-culture with
C2C12, serum derprivation by itself efficiently induced CD56+
cells to express the mature myogenic marker MYOGENIN and
undergo cell fusion to form multi-nucleated myotubes capable of
spontenous twitchning. In addition of the MYOGENIN+ mature
SMC fraction, a small fraction of myogenic precurosor cells
expressing PAX7 was also detected. To test engraftment potenital
in vivo, luciferase-expressing hESC-derived CD73+/CD56+
cells were transplanted into cardiotoxin-injured tibialis anterior
(TA) muscles of immunocompromised (SCID/Beige) mice and
monitored noninvasively. A substantial fraction of cells did
not survive the first week of transplantation due to cell death.
However, the transplanted cells stablized and persisted over
a period of 6 months forming 7% of the myofibers in the
host muscle as determined by human-specific laminin. The
long-term engraftment of the hESC-derived SMCs suggests the
persistence of myogenic progenitor cells that can contribute
to prolonged rounds of regneration. In a different approach,
myogenic differentiation of hESCs was induced by formation
of floating cell spheres called embryoid bodies (EBs) followed
by attachment on gelatin in media containing FBS and
epidermal growth factor (EGF) (Zheng et al., 2006). After
4 weeks in culture, expression of early myogenic markers
MET (HGFR), PAX7 and MYOD was detected but cells
failed to express mature myogenic markers or form myotubes,
highlighting the poor efficiency of spontaneous myogenic
differentiation methods. Nonetheless, transplantation of these
early myogenic cells into cardiotoxin-injured TA muscles
of immunocompromised (NOD-SCID) mice allowed further
maturation and incorporation of some transplanted cells into
the host myofibers, indicating that the ex vivo differentiation
conditions were missing critical myogenic induction cues. A
similar EB- and serum-based approach was optimized further
through elaborate dissociation and re-cultivation of EBs leading
to better myogenic differentiation of hESCs and hiPSCs in vitro
and in vivo (Awaya et al., 2012). Significantly, teratoma formation
was not observed in any of the grafted mice in the studies
mentioned above.
Transgenic Methods for Myogenic
Differentiation of hPSCs
Reported methods for the generation of SMCs from hPSCs are
invariably inefficient, overlong and usually involve cell sorting
for enrichment, especially if the small fraction of myogenic
progenitors/SCs with the highest regenerative potential is
desired. To overcome these limitations, several studies described
the use of ectopic expression of myogenic specification factors in
hPSCs or hPSC derivatives as a means to enhance and accelerate
the myogenic differentiation process. One such myogenic factor
is MYOD which is one of the earliest examples of “master”
transcription factors that are capable of transdifferentiating cells
from one lineage (e.g., fibroblasts) into another (skeletal muscle)
(Davis et al., 1987). Benefitting from this approach, Tedesco and
colleagues demonstrated the potential to generate engraftable
myogenic cells from genetically-corrected hiPSCs derived from
patients with limb-girdle muscular dystrophy 2D (LGMD2D), a
disease caused by mutations in the gene encoding α-sarcoglycan
(Tedesco et al., 2012). The patient-specific hiPSCs were
differentiated into mesodermal progenitors (mesoangioblast-like
or HIDEMs) that were genetically corrected with a lentiviral
vector carrying the gene encoding human α-sarcoglycan under
the control of a muscle-specific promoter. To induce terminal
differentiation, HIDEMs were transduced with a lentiviral vector
containing tamoxifen-inducible MYOD (MYOD-ER). Following
transplantation of the correctedMYOD-ER–expressing HIDEMs
in the TA muscles of immune-deficient Sgca-null/SCID/beige
mouse and daily administration of tamoxifen (for 7 days),
substantial engraftment and formation of donor-derived muscle
fibers expressing α-sarcoglycan were observed. In addition,
intra-arterial transplantation of the genetically corrected
HIDEMs led to colonization of the skeletal muscle downstream
of the injection site. Another muscular dystrophy, Miyoshi
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myopathy, was also recently modeled using ectopic expression of
MYOD in patient-derived hiPSCs followed by phenotypic rescue
by expression of full-length DYSFERLIN which is mutated in the
disease (Tanaka et al., 2013).
In a related work, Goudenege and colleagues attempted
initially the direct myogenic conversion of hESCs into SMCs
without passing through a mesodermal stage through the
ectopic expression of MYOD using adenoviruses but the
efficiency of myogenic conversion was unexpectedly very poor
(Goudenege et al., 2012). By differentiating hESCs first to
mesenchymal-like CD73+ cells followed byMYOD transduction,
the authors achieved a much higher myogenic conversion.
Upon transplantation into cardiotoxin-injured TA muscles of
immunocompromised mouse model of DMD (Rag/mdx), a high
level of engraftment in host muscles was observed. Interestingly,
the total number of human myofibers was significantly higher
in the muscles injected with the hPSC-derived SMCs than
in muscles injected with the same number of control human
myoblasts. This is a surprising finding as MYOD is a marker
of activated SCs (i.e., myoblasts) and suggests that the MYOD-
expressing hPSC-derived myoblasts have a higher engraftment
potential than their primary counterparts. Again, no teratoma
was observed in the muscles transplanted with hPSCs or with
hPSC-derived cells (Goudenege et al., 2012). A separate study
attributed the observed resistance of hPSCs to MYOD-mediated
induction of myogenesis to the absence of the chromatin-
modifying factor BAF60C. When hESCs were transduced with
exogenous BAF60C followed by MYOD, efficient conversion
of hESCs into myosin heavy chain (MYHC)-positive SMCs
was observed (Albini et al., 2013). Alternatively, we have
shown that direct myogenic conversion of ground-state hiPSCs
from healthy or DMD donors into SMCs can be achieved
within 3–5 days of Doxycycline-induced expression of MYOD
(Abujarour et al., 2014). It is unclear why MYOD-directed
myogenesis in our system did not require ectopic expression
of BAF60C. One possibility is that we cultured hiPSCs in
a small molecule-supplemented media under feeder cell-free
conditions that maintained hiPSCs in a ground state resembling
the naïve stage of pluripotency (Valamehr et al., 2014) and
possibly enhanced a more efficient MYOD-mediated myogenic
conversion. A direct MYOD-mediated differentiation method
has also been successfully demonstrated using MYOD-encoding
modified RNA and hiPSCs derived using similar mRNAs
encoding reprogramming factors, indicating that iPSCs and
specialized derivatives could be generated using safer non-
integrating methods (Warren et al., 2010).
The ectopic expression of MYOD is an attractive approach
as it dramatically accelerates the generation of SMCs from
hPSCs (from > 5 weeks to few days) and might have a safer
profile due to its tumor suppression activity (Dey et al., 2013).
However, the MYOD-based method yields mostly mature SMCs
that are predicted to have limited proliferative and regenerative
capacity compared with immature/inactivated SCs (Montarras
et al., 2005). However, with the ability of MYOD-induced hPSC-
derived myoblasts to engraft efficiently into injured muscles of
immunocompromised mice (Goudenege et al., 2012), a direct
comparison of the engraftment potential of hPSC-derived SMCs
generated using the MYOD method vs. other methods will be
helpful.
Using a different approach and learning from their previous
studies in mouse (Darabi et al., 2011a,b), Darabi and colleagues
relied on the ectopic expression of the myogenic factor PAX7,
archetypical marker of adult SCs, to generate myogenic
progenitors/SCs from hPSCs, (Darabi et al., 2012; Wang and
Rudnicki, 2012). hiPSCs and hESCs were modified with a
doxycycline-inducible lentiviral vector encoding PAX7 and
GFP (separated by IRES). Unlike the direct MYOD-mediated
approach, hiPSC/hESCs were first differentiated into a paraxial
mesoderm stage (marked by high BRACHYURY expression)
using EB based method and serum-rich media, followed
by PAX7 (and GFP) induction and cell sorting based on
GFP expression. The sorted cells showed progenitor-like
characteristics exhibiting high proliferative capacity and minimal
signs of terminal differentiation when cultured in the presence
of Dox, FGF, and serum. Upon culture in differentiation
media (with 2% horse serum) and withdrawal of Dox and
FGF, the myogenic progenitors differentiated efficiently into
multinucleated myotubes with only rare cells maintaining
PAX7 expression. To test their myogenic potential in vivo,
the progenitor cells expressing transgenic PAX7 were injected
into cardiotoxin-injured TA muscles of immunocompromised
DMD mouse model (NSG-mdx4Cv). The hPSC-derived
progenitors led to considerable engraftment that was much
higher than that observed with control human primary
myoblasts. Injection with the hPSC-derived progenitors led to
restoration of Dystrophin expression in the dystrophic muscles
and significant functional improvement as demonstrated by
increased isometric tetanic force, absolute force, and specific
TABLE 1 | Methods for the myogenic differentiation of hPSCs.
Differentiation methods Efficiency Time Myogenic stage Scale up Complexity**
Transgenic MyoD High Fast Mostly mature High* High
Pax7 High Medium Mostly progenitors High High
Non-transgenic Co-culture Low Slow Mixed Medium Medium
EBs Low Slow Mixed Medium Medium
Small molecules Medium Medium Mixed Medium Low (as monolayer)
*When scale up is carried during the stage of mesodermal differentiation.
**Includes regulatory complexity.
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force. Interestingly, transplantation of primary myoblasts did
not result in improvement of any of these functional parameters.
In addition, PAX7+ hPSC-derived progenitor cells were
detected within the sarcolemma of myofibers, indicating that
hPSC-derived progenitors seeded the SC compartment. This
contribution to the stem cell niche was associated with long-term
engraftment of hPSC-derived progenitors that was sustained
close to a year after transplantation into NSG mice.
Use of Small Molecules
Non-transgenic methods for the differentiation of hPSCs,
whether as a monolayer culture or as EBs, into SMCs remain
inefficient and overlong. One promising approach to improve
the myogenic differentiation efficiency of hPSCs is the use
of small molecules to inhibit or activate relevant signaling
pathways. Similar chemical approaches have been applied
successfully to enhance the efficiency of hiPSC generation,
culture (Valamehr et al., 2012, 2014) and differentiation into
multiple lineages (Xu et al., 2013b). Two groups recently reported
enhanced myogenic differentiation of hESCs/hiPSCs through the
sequential treatment with a WNT activator, the small-molecule
glycogen synthase kinase-3 (GSK-3) inhibitor CHIR99021, and
fibroblast growth factor 2 (FGF2) in serum-free media (Borchin
et al., 2013; Shelton et al., 2014). Interestingly, the two methods
reported relatively high levels of PAX7+ myogenic progenitor
cells ranging between 18% by week 5 (Borchin et al., 2013)
and 43% by week 7 (Shelton et al., 2014). Combined with
their two-step differentiation method, Borchin and colleagues
described a stringent cell sorting strategy for the enrichment
of PAX3+/PAX7+ myogenic progenitors based on the negative
selection markers HNK (neural crest) and nicotinic acetylcholine
receptor (AChR; mature skeletal marker) and positive selection
markers CXCR4 and MET (Borchin et al., 2013). The new cell
sorting strategy led to efficient enrichment of PAX3+/PAX7+
cells, with MET appearing to be the more critical marker in
this sorting strategy. This is the first example demonstrating the
ability to obtain skeletal myogenic PAX7+ progenitor cells in
high purity from hPSCs without genetic modification. It will
be interesting in the future to explore how the engraftment
potential of these purified myogenic progenitors compare to that
of primary myoblasts isolated and ex vivo expanded from human
muscle.
In order to identify novel chemical modulators of the skeletal
muscle lineage, Xu and colleagues carried out a high-throughput
image-based screen using blastomere cells from a myf5-
GFP and mylz2 (myosin light polypeptide 2)-mCherry double
transgenic zebrafish line, with myf5 marking early myogenic
commitment and mylz2 marking terminal differentiation (Xu
et al., 2013a). Screening a library of 2400 small molecules
identified 28 chemicals that perturbed muscle development and
six that promoted myogenesis including three GSK3 inhibitors,
two calpain inhibitors, and one adenylyl cyclase activator,
forskolin. Combining the GSK3β inhibitor BIO, forskolin, and
FGF2 induced efficient skeletal muscle specification of hiPSCs,
indicating an effect conserved across species. Significantly, the
highest myogenic differentiation efficiency was observed when
the three factors were combined, compared to combinations
of two factors only, suggesting a synergistic effect. The hiPSC-
derived cells expressed muscle markers like PAX7, MYF5,
MYOD, MYOGENIN, andMYHC and formed mature myotubes
in vitro. Upon injection into cardiotoxin-injured TA muscles
of immunocompromised mice, the hiPSC-derived myogenic
progenitors contributed to muscle fibers and the SC pool in the
host muscle.
Summary
Major advances were made toward improving the generation
and selection of SMCs and myogenic progenitors from
hPSCs (Table 1). It is now possible to generate hPSC-derived
myogenic progenitors in high purity and when using ectopic
expression of myogenic factors to dramatically accelerate
differentiation and improve efficiency. The amelioration of the
DMD phenotype through the transplantation of hPSC-derived
myogenic progenitors expressing exogenous PAX7 provides a
proof of concept demonstrating the potential use of hPSCs
for cell therapy targeting degenerative muscle diseases (Darabi
et al., 2012). The use of small molecules is a promising
alternative approach to drive myogenic differentiation of hPSCs
into functional muscle progenitors without the use of transgenic
interventions. In addition, small molecules facilitate single
cell manipulation and increased clonogenicity of hiPSCs, and
with recent advances in gene editing technologies represent
important tools to facilitate gene correction and development
of autologous cell replacement therapies for DMD and other
muscular dystrophies (Valamehr et al., 2014; Li et al., 2015).
While hPSC-derived SMCs showed high engraftment and
regenerative potential in vivo, their contribution remains
localized as engrafted cells do not migrate more than few
microns from the site of injection (Goudenege et al., 2012;
Skuk et al., 2014). The limited migration of engrafted hPSC-
derived SMCs/progenitors (and their primary counterparts) is
a major limitation to their application as a cell therapy for
systemic diseases like DMD, and other cell types that can be
administered systemically are being investigated in preclinical
and clinical studies (Tedesco et al., 2010; Meregalli et al., 2014).
Besides SCs/ myoblasts, other muscle-associated cell types such
as mesoangioblasts, pericytes, muscle side-population cells and
CD133 + cells have been considered (Meregalli et al., 2014)
and derived from hPSCs (Tedesco et al., 2012) as a potential
treatment for muscle wasting. These cell types have variable
features (e.g., systemic migration, proliferative potential, surface
markers) and variable capacities to engraft and contribute to
muscle repair. Therefore, one of the major challenges facing the
field is identifying the optimal cell type(s) that is most suited
to treat the multiple and variable diseases of the skeletal muscle
system.
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